- 全部删除
您的购物车当前为空
Naldemedine tosylate (S-297995)为具口服活性的μ-阿片受体拮抗剂(PAMORA)。其对重组人源μ-、δ-及κ-阿片受体展现出高亲和力(Ki分别为0.34,0.43,0.94 nM)及强拮抗效果(IC50分别为25.57,7.09,16.1 nM)。适用于研究由阿片类物质引起的便秘(OIC)。Naldemedine tosylate也被预测可能与SARS-CoV2 3CLpro结合。

Naldemedine tosylate (S-297995)为具口服活性的μ-阿片受体拮抗剂(PAMORA)。其对重组人源μ-、δ-及κ-阿片受体展现出高亲和力(Ki分别为0.34,0.43,0.94 nM)及强拮抗效果(IC50分别为25.57,7.09,16.1 nM)。适用于研究由阿片类物质引起的便秘(OIC)。Naldemedine tosylate也被预测可能与SARS-CoV2 3CLpro结合。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 12,200 | 10-14周 | |
| 50 mg | ¥ 15,900 | 10-14周 | |
| 100 mg | ¥ 24,100 | 10-14周 |
Naldemedine tosylate 相关产品
| 产品描述 | Naldemedine tosylate (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA) with high binding affinities (K_i = 0.34, 0.43, 0.94 nM) and potent antagonist activities (IC_50 = 25.57, 7.09, 16.1 nM) towards human recombinant μ-, δ-, and κ-opioid receptors, respectively. It is utilized in research on opioid-induced constipation (OIC). Additionally, Naldemedine tosylate is anticipated to interact with the 3CL proenzyme encoded by the SARS-CoV-2 genome. |
| 别名 | S-297995 tosylate |
| 分子量 | 742.84 |
| 分子式 | C39H42N4O9S |
| CAS No. | 1345728-04-2 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容